RESEARCH & DEVELOPMENT PARTNERS
Our novel drug development pipeline was built through collaborations with top University researchers, industry leaders in novel delivery and manufacturing processes, and respected hospitals who care about their patients.
Our intellectual property portfolio of complex therapeutic mixtures currently includes: 6 issued US patents and 3 issued international patents as well as 18 US and 49 international patent-pending applications.
Discovery Partners

University of Athens, Greece

Chaminade University

Michigan State University

University of Seville, Spain

Preclinical Partners

National Research Council, Canada

Michigan State
University

University of Cadiz,
Spain

University of Hawaii
Animal Models used for establishing a Proof-of-Concept for our Optimized Therapeutic Mixtures for the treatment of Heart Failure.

The University of
Lethbridge, Canada

Clinical Trial Partners

FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research around the world.
FHI has been selected as our CRO to help with our go-to-market strategy and draft clinical trial protocol for our COVID-19 related, anti-inflammatory
OFFICIAL PRESS RELEASE 5/2/2022

Development Partners

Purisys, LLC

Catalent, Inc.
Here’s the latest from Gb Sciences
-
Andrea Small-Howard, Ph.D.